CTRL and neoplasm: To verify if STK24 mediates tumor PD‐L1 expression through an AKT activation‐dependent manner, we employed the AKT activation‐specific inhibitor MK2206 to treat Ctrl and Stk24 KO cells prior to IFN‐γ induction.